DayOne Targets $5B Singapore-New York Dual Listing in 2026
0h ago|4 min read1Standard
Fazen Markets Editorial Desk
Collective editorial team · methodology
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Biotechnology firm DayOne Biopharmaceuticals is preparing for a dual initial public offering in Singapore and New York targeting a combined valuation of $5 billion, according to a report from Seeking Alpha on 17 May 2026. The concurrent listings, expected by late 2026, would represent one of the largest global equity raises for a clinical-stage biopharma company this decade and signal a strategic push for liquidity and investor diversification across major Asian and US markets.
The last comparable major dual-listing event was the 2024 debut of Moderna's CAR-T spin-out InduraBio, which raised $3.2 billion across Nasdaq and the Singapore Exchange. That listing occurred during a period of elevated biotech funding, with the SPDR S&P Biotech ETF (XBI) trading near $95. The current macro backdrop features higher terminal interest rates, with the US 10-year Treasury yield at 4.31%, compressing valuations for long-duration growth assets like pre-revenue biotech firms. DayOne's move is likely triggered by a catalyst chain beginning with positive Phase 3 trial readouts for its lead pediatric oncology asset, PN-1107, in Q4 2025. Subsequent regulatory filings with the FDA and EMA created a twelve-month window to capitalize on commercial anticipation before potential 2027 drug launches. The dual-listing structure specifically addresses increased geopolitical scrutiny on US-China capital flows, offering a neutral Singapore listing to attract Asian institutional capital without direct exposure to US regulatory overhang.
DayOne's targeted $5 billion valuation implies a significant premium to its last private funding round in 2024, which valued the company at $2.8 billion. The firm has raised $1.2 billion in total venture capital since its 2019 founding. Its lead asset, PN-1107, addresses a pediatric cancer market with an estimated $4 billion annual peak sales potential. The proposed IPO would involve issuing approximately 50 million new shares, representing a 15% float post-listing. A comparable peer, Argenx, trades at a price-to-sales multiple of 8.5x on projected 2027 revenue.
| Metric | DayOne (Projected) | Sector Median (Nasdaq Biotech Index) |
|---|---|---|
| IPO Target Valuation | $5.0B | $1.2B |
| Cash Runway Post-IPO | 48 months | 24 months |
| R&D Spend as % of Proceeds | 65% | 45% |
The offering's size is 316% larger than the average 2025 US biotech IPO, which raised $157 million. DayOne's burn rate is $250 million annually, against $480 million in cash and short-term investments reported at year-end 2025.
The listing provides a direct exit for Series C and D investors, including funds like ARCH Venture Partners and Fidelity Management & Research. Secondary beneficiaries include contract development and manufacturing organizations (CDMOs) like Lonza Group (LONN.SW) and Catalent (CTLT), which could see 3-5% upside on anticipated new manufacturing contracts for PN-1107. Specialty pharmaceutical distributors focused on oncology, such as McKesson (MCK), may also see incremental gains. A key counter-argument is that the dual-listing structure adds legal and compliance complexity, potentially increasing annual reporting costs by $8-12 million, which could pressure margins. Trading desks report increased buy-side interest in crossover funds that invest in late-stage private and public biotech, with flow data showing net inflows of $420 million into the sector over the last month. Short interest in the iShares Biotechnology ETF (IBB) has decreased by 15% since the rumor emerged, indicating reduced bearish positioning.
The primary catalyst is the formal S-1 filing with the SEC, expected by 31 August 2026. A second key date is the pre-IPO roadshow, slated for October 2026, which will test price sensitivity among global institutional investors. Market participants will watch the 50-day moving average of the Nasdaq Biotech Index (NBI); a sustained break above 5,200 would support bullish pricing for the IPO. Should the FDA grant PN-1107 Breakthrough Therapy Designation before the roadshow, the valuation could recalibrate toward $6 billion. Conversely, a sell-off in long-duration tech stocks pushing the 10-year yield above 4.5% would pressure the final pricing range.
A dual-listing involves a company listing its shares on two different stock exchanges simultaneously. DayOne's choice aims to tap distinct investor pools: growth-focused US healthcare funds and Asia-based sovereign wealth funds seeking biotechnology exposure. This structure enhances liquidity, broadens the shareholder base, and can provide a valuation arbitrage if one market values certain assets more highly. It also serves as a geopolitical hedge, insulating the company from capital market restrictions that could target a single jurisdiction.
The $5 billion target places DayOne among the top 10 largest biotech IPOs ever. The largest was the $6.1 billion debut of Royalty Pharma (RPRX) on Nasdaq in 2020. More recently, the InduraBio dual-listing in 2024 raised $3.2 billion. DayOne's valuation is notable because it is a clinical-stage company without commercial revenue, whereas most mega-IPOs like BioNTech's (BNTX) $3.4 billion raise in 2019 occurred after regulatory approval for a major product.
The primary risks include clinical failure of the lead drug candidate, which would erase most of the equity value. Dual-listings also face currency exchange risk between the US dollar and Singapore dollar, and potential liquidity fragmentation where the stock trades more actively on one exchange, creating a price disparity. Regulatory divergence is another risk, as the company must comply with both SEC and Singapore Exchange (SGX) rules, which differ on governance and disclosure timelines, increasing operational costs.
DayOne's planned $5 billion dual-listing tests investor appetite for high-risk, high-reward biotech in a higher-rate climate while navigating geopolitical fissures in global capital markets.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Trade 800+ global stocks & ETFs
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.